DDInter1201 DDInter1658
Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy include metabolic abnormalities such as hypertriglyceridemia, insulin resistance, diabetes mellitus, and fatty liver disease. These metabolic abnormalities are often aggravated by excessive food intake, which is further aggravated by leptin deficiency, a protein secreted by adipose tissue. Administration of metreleptin results in improvement of metabolic symptoms including improvements in insulin resistance, reduced HbA1c and fasting glucose, reduced triglycerides, and reductions in food intake. Metreleptin is produced in _E. coli_ and differs from native human leptin by the addition of a methionine residue at its amino terminus. In February
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Metreleptin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Relugolix
Metreleptin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Metreleptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naloxegol
Metreleptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobimetinib
Metreleptin {u} may lead to a major life threatening interaction when taken with {v} Lumateperone
Metreleptin may cause a minor interaction that can limit clinical effects when taken with Relugolix
Metreleptin may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol
Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Metreleptin may lead to a major life threatening interaction when taken with Lumateperone